Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 3 Interventional

Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

NCT00012389
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
100
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 31, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

NCT00550277
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
LBH589
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Fort Myers, Florida • Gainesville, Georgia • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 31, 2026, 2:59 AM EDT
Terminated No phase listed Observational

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

NCT01652157
View directory record Official record
Conditions
Fibrosing Colonopathy
Interventions
ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
0 Months to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
123
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

NCT02227875
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
94
States / cities
Chandler, Arizona • Bell Gardens, California • Fresno, California + 84 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 31, 2026, 2:59 AM EDT
Completed No phase listed Observational

Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database

NCT01353677
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
2 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Gainesville, Florida • Rochester, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

NCT04227977
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
JuxtaFlow System
Device
Lead sponsor
3ive Labs
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Cleveland, Ohio • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 31, 2026, 2:59 AM EDT
Recruiting No phase listed Observational

Florida Center for Brain Tumor Research

NCT00811148
View directory record Official record
Conditions
Brain Tumors
Interventions
Tissue Bank
Procedure
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

NCT04435626
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 31, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Interventions
MRTX849, Docetaxel
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
112
States / cities
Cerritos, California • Duarte, California • Glendale, California + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

NCT05130268
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone
Drug
Lead sponsor
American Heart Association
Other
Eligibility
21 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
103
States / cities
Fairhope, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1)

NCT03107949
View directory record Official record
Conditions
Ventilator Induced Diaphragm Dysfunction
Interventions
Lungpacer DPTS (Diaphragm Pacing Therapy System)
Device
Lead sponsor
Lungpacer Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Gainesville, Florida • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 31, 2026, 2:59 AM EDT
Not listed Phase 3 Interventional

Repetitive Behavior Disorders in People With Severe Mental Retardation

NCT00491478
View directory record Official record
Conditions
Mental Retardation, Stereotyped Behavior, Self-Injurious Behavior, Compulsive Behavior
Interventions
sertraline
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
2
States / cities
Gainesville, Florida • Morganton, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2007 · Synced Oct 31, 2026, 2:59 AM EDT
Completed No phase listed Observational

OPsumit USers Registry

NCT02126943
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Opsumit (macitentan)
Drug
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
144
States / cities
Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 31, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT02567435
View directory record Official record
Conditions
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Temsirolimus, Vincristine Sulfate, Vinorelbine
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
355
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 210 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

NCT00367835
View directory record Official record
Conditions
ADHD
Interventions
SPD503 (Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 31, 2026, 2:59 AM EDT
Completed No phase listed Observational

A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults

NCT03505125
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Gainesville, Florida • Decatur, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole in Children With GERD

NCT00141817
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole for approximately 9 weeks.
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Year to 11 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Enhances Human Immune Function and Reduces Illness

NCT01398150
View directory record Official record
Conditions
Healthy Humans
Interventions
Beverage made to look like the cranberry beverage, Beverage made from cranberry compounds
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

NCT00294190
View directory record Official record
Conditions
Small Cell Lung Cancer, Carcinoma, Small Cell
Interventions
Topotecan
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

NCT00001066
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 31, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

NCT02669966
View directory record Official record
Conditions
ESRD, Hepatitis C
Interventions
Kidney transplantation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 31, 2026, 2:59 AM EDT
Active, not recruiting No phase listed Observational

ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

NCT03973372
View directory record Official record
Conditions
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Redwood City, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 2:59 AM EDT